Utilization of immunotherapy among patients with stage 4 melanoma: An analysis of the National Cancer Database from 2012 to 2016

J Am Acad Dermatol. 2021 Mar;84(3):811-814. doi: 10.1016/j.jaad.2020.06.031. Epub 2020 Jun 14.

Authors

Parth V Shah¹, Jennifer N Choi¹, Lori Fiessinger², Beatrice Nardone¹, Cuong V Nguyen¹, Walter Liszewski³

Affiliations

¹ Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Dermatology, University of Minnesota, Minneapolis, Minnesota.
³ Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Cancer Epidemiology, Northwestern University, Chicago, Illinois. Electronic address: wjliszewski@gmail.com.

PMID: 32553633
DOI: 10.1016/j.jaad.2020.06.031

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Immunological / therapeutic use*
Databases, Factual / statistics & numerical data
Female
Humans
Immunotherapy / methods
Immunotherapy / statistics & numerical data*
Immunotherapy / trends
Male
Melanoma / diagnosis
Melanoma / drug therapy*
Melanoma / immunology
Middle Aged
Neoplasm Staging
Practice Patterns, Physicians' / statistics & numerical data*
SEER Program / statistics & numerical data
Skin Neoplasms / diagnosis
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology

Substances

Antineoplastic Agents, Immunological